Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBITDA (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed EBITDA for 3 consecutive years, with -$15.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 2.62% to -$15.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$66.4 million through Dec 2025, down 34.99% year-over-year, with the annual reading at -$66.4 million for FY2025, 34.99% down from the prior year.
  • EBITDA hit -$15.7 million in Q4 2025 for Compass Therapeutics, down from -$14.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.7 million in Q1 2023 to a low of -$19.9 million in Q2 2025.
  • Historically, EBITDA has averaged -$13.1 million across 3 years, with a median of -$13.0 million in 2023.
  • Biggest five-year swings in EBITDA: fell 0.17% in 2024 and later crashed 52.58% in 2025.
  • Year by year, EBITDA stood at -$12.9 million in 2023, then dropped by 18.23% to -$15.3 million in 2024, then fell by 2.62% to -$15.7 million in 2025.
  • Business Quant data shows EBITDA for CMPX at -$15.7 million in Q4 2025, -$14.2 million in Q3 2025, and -$19.9 million in Q2 2025.